吡西卡尼治疗房颤随机对照试验的Meta分析  

A Meta-analysis of Randomized Controlled Trials on Pilsicainide in Treatment of Atrial Fibrillation

作　　者：郭宗文[1] 王丹丹[1] 王徐乐[1] 黄从新[1] 

机构地区：[1]武汉大学人民医院心内科,武汉市430060

出　　处：《广西医学》2014年第11期1568-1572,共5页Guangxi Medical Journal

基　　金：国家科技支撑计划项目(2011BAI11B12)

摘　　要：目的评价吡西卡尼治疗心房颤动的有效性及安全性。方法计算机检索Pub Med、EMbase和Cochrane Library数据库,查找所有有关吡西卡尼治疗心房颤动的临床随机对照试验(RCT),检索时限均为建库至2013年12月31日。由两名研究者按照纳入与排除标准独立筛选文献、提取资料和评价质量后,进行Meta分析。结果共纳入5个研究,376例患者。Meta分析结果显示:吡西卡尼组房颤转复率高于对照组(P=0.03);吡西卡尼治疗阵发性房颤、持续性房颤均表现出优势,但与对照组相比,两组房颤转复率差异均无统计学意义(P<0.05);两组药物不良反应发生率差异无统计学意义(P>0.05)。结论吡西卡尼治疗房颤疗效确切,不良反应少。Objective To assess the effectiveness and safety of pilsicainide in the treatment of atrial fibrillation（ AF）. Methods All randomized controlled trials（ RCTs） on pilsicainide for the treatment of AF were retrieved from databases including Pub Med,EMbase and Cochrane Library,the time ranged from the date of databases＇ initial construction to December 31,2013. The data extraction,based on the inclusion and exclusion criteria,and quality assessment of included RCTs were conducted by two reviewers independently. And then a Meta-analysis was conducted. Results Five RCTs involving 376 patients were included. The results of Meta-analysis were as follows. The successful conversion rate of pilsicainide group was superior to that of control group（ P = 0. 03）. Pilsicainide showed higher successful conversion rates of paroxysmal AF and persistent AF compared with the controls,but there were no statistical differences between two groups（ P〉0. 05）. No significant difference was observed in the incidence of adverse drug reactions between two groups（ P〉0. 05）. Conclusion Pilsicainide is effective in the treatment of AF,with less adverse reactions.

关 键 词：吡西卡尼 心房纤颤 系统评价 META分析 随机对照试验 

分 类 号：R541.7[医药卫生—心血管疾病]